Second-Line and MDR-TB Regimens
- Previous year questions on Second-Line and MDR-TB Regimens for NEET PG (National Eligibility cum Entrance Test - Postgraduate), from the Pharmacology section of the exam.
- Most questions here come from previous-year papers of Indian postgraduate medical entrance and licensing exams; where a paper and year are recorded the question carries them. The image-based questions are original vignettes written around an openly licensed figure, and were never asked in any exam.
- 6 live questions in Second-Line and MDR-TB Regimens.
- 1 of 6 questions carries a verified exam year: 2019.
- Pharmacology is worth about 20 of 300 questions on the exam. See every subject’s weightage.
- Question set last updated 6 Sept 2026.
Q1.According to the recent classification of antitubercular drugs, which of the following drugs is classified under Group II?
- AEthambutol
- BStreptomycin✓ Correct answer
- CLevofloxacin
- DImipenem
Q2.Which of the following statements is false regarding bedaquiline?
- AInhibits mycobacterial cell wall synthesis✓ Correct answer
- BCauses QT prolongation
- CHalf-life is very long
- DIndicated for MDR TB and XDR TB
Q3.Which ATT will cause transient memory loss
- AEthionamide
- BINH✓ Correct answer
- CEthambutol
- DPyrazinamide
Q4.Which anti tubercular drug will cause transient memory loss?
- AEthionamide
- BINH✓ Correct answer
- CEthambutol
- DPyrazinamide
Q5.Which of the following is the new drug for the treatment of multi drug resistant tuberculosis?
- ABedaquiline✓ Correct answer
- BLinezolide
- CLevofloxacin
- DCefepime
Q6.MDR TB must be treated for at least ?
- A12 months
- B18 months
- C20 months✓ Correct answer
- D36 months
Answer key
Q1: B. Streptomycin; Q2: A. Inhibits mycobacterial cell wall synthesis; Q3: B. INH; Q4: B. INH; Q5: A. Bedaquiline; Q6: C. 20 months.
Other topics in Pharmacology
- Pharmacokinetics
- Pharmacodynamics
- Adverse Drug Reactions and Pharmacovigilance
- Clinical Trials and Drug Development
- Pharmacokinetics: Applied Calculations
- ANS Overview and Cholinergic Agonists
- Sympathomimetics
- Parasympatholytics
- Sympatholytics
- Antiglaucoma Agents
- Antianginal Agents
- Drugs for Cardiac Failure
- Antihypertensives
- Diuretics
- Antiarrhythmic Agents
- Lipid-Lowering Agents
- Drugs Acting on the RAAS
- Antidiuretic Agents
- Sedative-Hypnotics
- Antiepileptics: Sodium Channel and GABAergic Agents
- Antiepileptics: Newer and Broad-Spectrum Agents
- Antipsychotic Agents
- Drugs for Mania and Mood Stabilization
- Antiparkinsonian Drugs
- Antidepressants and Anxiolytics
- Opioids: Classification and Actions
- Semisynthetic and Synthetic Opioid Analgesics
- Opioid Receptor Antagonists
- Ethanol and Other Alcohols
- Drugs for Alzheimer's and Neurodegenerative Disease
- Principles of Antimicrobial Use and Resistance
- Antimalarials
- Folate Antagonists, Quinolones and Urinary Antiseptics
- Drugs Targeting the 30S Ribosomal Subunit
- Drugs Targeting the 50S Ribosomal Subunit
- Antiretroviral Therapy for HIV
- Penicillins
- Cephalosporins, Carbapenems and Glycopeptides
- Other Antibacterial Agents
- Antiprotozoals and Anthelmintics
- Antifungals
- First-Line Antitubercular Drugs
- Antileprotic Drugs
- Antivirals: Non-Retroviral Agents
- Hypothalamic and Pituitary Hormones
- Thyroid Hormones and Antithyroid Drugs
- Corticosteroids
- Drugs for Osteoporosis and Calcium Disorders
- Antidiabetics: Oral Agents
- Antidiabetics: Insulins and Injectables
- Estrogens, Progestins and OCPs
- Androgens and Erectile Dysfunction Therapy
- Uterine Stimulants and Relaxants
- NSAIDs
- Drugs for Migraine and Gout
- DMARDs for Rheumatoid Arthritis
- Immunosuppressants and Immunomodulators
- Antihistamines
- Antiplatelet, Fibrinolytic and Antifibrinolytic Agents
- Hematinics
- Anticoagulants
- Drugs for Asthma and COPD
- Drugs for Peptic Ulcer and IBD
- Antiemetics, Prokinetics and Laxatives
- Cell Cycle-Specific Chemotherapy
- Cell Cycle-Nonspecific Chemotherapy
- Monoclonal Antibody Therapeutics
- Cytokines, Growth Factors and Targeted Agents